Sponsor:
Noom Inc.
Code:
NCT07588984
Conditions
Obesity & Overweight
Weight Loss
Preventative Health
Body Weight
Cardiovascular Disease Risk Factor
Eligibility Criteria
Sex: All
Age: 18 - 64
Healthy Volunteers: Not accepted
Interventions
Noom Weight
Free Tier
Education-only control
Semaglutide
Tirzepatide
Brief summary:
Conditions
Obesity & Overweight
Weight Loss
Preventative Health
Body Weight
Cardiovascular Disease Risk Factor
Study ID
NCT07588984
Start date
May 26, 2026
Status verified date
May, 2026
Completion date
May, 2029
Anticipated
Primary completion date
May, 2029
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 64
Healthy Volunteers: Not accepted
Enrollment
2541 participants
Anticipated
Arms
Education only (control)
Noom Weight
Standard GLP-1Rx
Microdose GLP-1Rx
Noom Plus
Noom Plus Microdose
Noom Free Tier (control)
Proactive Health
Interventions
Noom Weight
Free Tier
Education-only control
Semaglutide
Tirzepatide
Microdose semaglutide
Microdose tirzepatide
Primary outcome measure
Central contacts
Locations
Noom, Inc.
Recruiting
Princeton, New Jersey, United States, 08542
Contacts
Sponsor
Noom Inc.
Last update posted
Nov 16, 2026
Last verified
May, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Noom Inc. on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.